DNLI

DNLI

Denali Therapeutics Inc

Denali Therapeutics Inc. develops therapeutics for neurodegenerative and lysosomal storage diseases, focusing on conditions like Parkinson's, Alzheimer's, and various types of storage disorders through enzyme replacement and targeted therapies.

โš•๏ธ Healthcare NASDAQ Listed 2017 $ USD
$1,000 invested 5 years ago โ†’$477today

Score Overview

1 Year
Scoreโ€”
Net Growth0.88%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score2.9
Net Growth-74.83%
Net Trend40%
Net Income Consistencyโ€”
Rev Growth-100.00%
Rev Trend40%
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-476.08%
Net Trend44%
Net Income Consistency
Rev Growthโ€”
Rev Trend44%
Revenue Consistency

See the full market ranking โ†’

Denali Therapeutics Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 335M to $ 0.00 and net income went from $ 71M to -$ 512M. Revenue increased in 2 of those 5 years; net income in 2.

Denali Therapeutics Inc currently holds a 5-year HDB Score of 2.9 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 25.27โ€”
1 Year2025-08-12
$ 13.2291.15%
5 Years2021-08-12
$ 52.93-52.26%
All Time2017-12-08
$ 21.4517.81%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 508M$ 987M
2025$ 0.00-$ 512M$ 867M
2024$ 0.00-$ 422M$ 832M
2023$ 330M-$ 145M$ 1.03B
2022$ 108M-$ 325M$ 1.33B
2021$ 48M-$ 290M$ 865M
2020$ 335M$ 71M$ 1.46B
2019$ 26M-$ 197M$ 415M
2018$ 129M-$ 36M$ 464M
IPO2017$ 0.00-$ 88M$ 406M

Explore beyond DNLI

You're looking at Denali Therapeutics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies